Shots:

• The P-II (KRYSTAL-7) & P-Ib (KRYSTAL-1) cohort evaluates adagrasib (400mg, BID) + pembrolizumab for NSCLC harbor KRAS^G12C mutation. 75 patients were enrolled for safety with a median follow-up of 3.5mos.
• The results showed favorable tolerability & promising preliminary efficacy along with clinical activity across all PD-L1 subgroups with ORR (49%), increases in ALT/AST @26 & 37 days, 9% increase in grade 3 LFT, 1 with new-onset treatment-related ALT/AST increase after 3mos., ORR (56%) in response-evaluable patients
• 7 were enrolled in (KRYSTAL-1) with a median follow-up of 19.3mos. with ORR (57%) & DCR (100%), 4 maintained responses for ~9mos. & 2 continued in treatment. The safety was consistent with (KRSTYAL-7) with no grade 4-5 TRAEs, treatment discontinuation due to TRAEs in combination & pembrolizumab in 2 patients

Ref: PRNewswire | Image: Mirati